Kohei Kaku

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 66

Top Topics

Body Mass Index

Glycemic Control

Clinical Practice

Top Venues

Journal of diabetes investigation

Diabetes, obesity & metabolism

Expert opinion on drug safety

Endocrinology, diabetes & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Shuhei Nakanishi, Masashi Shimoda, Tomohiko Kimura, Junpei Sanada, Yoshiro Fushimi, Yuichiro Iwamoto, Hideyuki Iwamoto, Kazunori Dan, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
The impact of handgrip strength and waist circumference on glycemic control: Prospective, observational study using outpatient clinical data in Japanese patients with type 2 diabetes mellitus. Journal of diabetes investigation (2024)
Shuhei Nakanishi, Masashi Shimoda, Tomohiko Kimura, Junpei Sanada, Yoshiro Fushimi, Yuichiro Iwamoto, Hideyuki Iwamoto, Kazunori Dan, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
The impact of handgrip strength and waist circumference on glycemic control: Prospective, observational study using outpatient clinical data in Japanese patients with type 2 diabetes mellitus. Journal of diabetes investigation 15 (7) (2024)
Shuhei Nakanishi, Masashi Shimoda, Tomohiko Kimura, Junpei Sanada, Yoshiro Fushimi, Yuichiro Iwamoto, Hideyuki Iwamoto, Kazunori Dan, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
The impact of handgrip strength and waist circumference on glycemic control: Prospective, observational study using outpatient clinical data in Japanese patients with type 2 diabetes mellitus. Journal of diabetes investigation 15 (7) (2024)
Yuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda, Yuka Nogami, Yoshiko Shirakiya, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice. Diabetes, obesity & metabolism 26 (6) (2024)
Yuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda, Yuka Nogami, Yoshiko Shirakiya, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice. Diabetes, obesity & metabolism (2024)
Katsuhiko Hagi, Kenji Kochi, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki
Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus. Journal of diabetes investigation 15 (9) (2024)
Yuichiro Iwamoto, Tomohiko Kimura, Masashi Shimoda, Yuichi Morimoto, Yuki Watanabe, Takashi Itoh, Taku Sasaki, Shigehito Mori, Masato Kubo, Haruka Takenouchi, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
C-peptide index at 2 h post-meal is a useful predictor of endogenous insulin secretory capacity and withdrawal from insulin therapy in subjects with type 2 diabetes. Diabetes, obesity & metabolism 26 (7) (2024)
Katsuhiko Hagi, Kenji Kochi, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki
Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data-driven cluster analysis: A post-hoc analysis of imeglimin clinical trial data. Diabetes, obesity & metabolism (2024)
Yuichiro Iwamoto, Tomohiko Kimura, Masashi Shimoda, Yuichi Morimoto, Yuki Watanabe, Takashi Itoh, Taku Sasaki, Shigehito Mori, Masato Kubo, Haruka Takenouchi, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
C-peptide index at 2 h post-meal is a useful predictor of endogenous insulin secretory capacity and withdrawal from insulin therapy in subjects with type 2 diabetes. Diabetes, obesity & metabolism (2024)
Katsuhiko Hagi, Kenji Kochi, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki
Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data-driven cluster analysis: A post-hoc analysis of imeglimin clinical trial data. Diabetes, obesity & metabolism 26 (9) (2024)
Hideyuki Iwamoto, Tomohiko Kimura, Yoshiro Fushimi, Masahiro Iwamoto, Fuminori Tatsumi, Junpei Sanada, Yuichiro Iwamoto, Yukino Katakura, Masashi Shimoda, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching. Diabetes, obesity & metabolism (2024)
Katsuhiko Hagi, Kenji Kochi, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki
Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus. Journal of diabetes investigation 15 (9) (2024)
Yuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda, Yuka Nogami, Yoshiko Shirakiya, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice. Diabetes, obesity & metabolism 26 (6) (2024)
Katsuhiko Hagi, Kenji Kochi, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki
Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus. Journal of diabetes investigation 15 (9) (2024)
Katsuhiko Hagi, Kenji Kochi, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki
Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus. Journal of diabetes investigation (2024)
Shuhei Nakanishi, Masashi Shimoda, Tomohiko Kimura, Junpei Sanada, Yoshiro Fushimi, Yuichiro Iwamoto, Hideyuki Iwamoto, Kazunori Dan, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
The impact of handgrip strength and waist circumference on glycemic control: Prospective, observational study using outpatient clinical data in Japanese patients with type 2 diabetes mellitus. Journal of diabetes investigation 15 (7) (2024)
Toshinari Takamura, Kohei Kaku, Akihiro Yoshida, Hiromi Kusakabe, Hiroyuki Nakamura, Hideki Suganami
Reductions in liver enzymes are associated with anti-hyperglycaemic and anti-obesity effects of tofogliflozin in people with type 2 diabetes: Post-hoc analyses. Endocrinology, diabetes & metabolism (2023)
Katsuhiko Hagi, Kenji Kochi, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki
Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials. Journal of diabetes investigation (2023)
Tomohiko Kimura, Yukino Katakura, Masashi Shimoda, Fumiko Kawasaki, Mizuho Yamabe, Fuminori Tatsumi, Michihiro Matsuki, Yuichiro Iwamoto, Takatoshi Anno, Yoshiro Fushimi, Shinji Kamei, Yukiko Kimura, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto, null null
Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study). Diabetes, obesity & metabolism (2023)
Katsuhiko Hagi, Masahiro Nitta, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki
Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Journal of diabetes investigation (2023)
Kohei Kaku, Yayoi Nakayama, Junko Yabuuchi, Yusuke Naito, Keizo Kanasaki
Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study. Expert opinion on drug safety (2023)
Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Hristo Lliev, Atsutaka Yasui
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study. Expert opinion on drug safety 21 (10) (2022)
Daisuke Yabe, Yuichiro Yamada, Kohei Kaku, Tomoyuki Nishida, Toshihiro Sato, Yutaka Seino
Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index. Journal of diabetes investigation 13 (7) (2022)
Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Seiko Mizuno, Daisuke Nitta
Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study. Expert opinion on drug safety (2022)
Kohei Kaku, Christoph Wanner, Stefan D Anker, Stuart Pocock, Atsutaka Yasui, Michaela Mattheus, Søren S Lund
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease. Diabetes, obesity & metabolism 24 (4) (2022)
Yasuhiro Matsubayashi, Alkihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku, Hirohito Sone
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. Diabetes, obesity & metabolism 24 (12) (2022)
Kaio Takahashi, Takatoshi Anno, Haruka Takenouchi, Hideyuki Iwamoto, Megumi Horiya, Yukiko Kimura, Fumiko Kawasaki, Kohei Kaku, Koichi Tomoda, Hideaki Kaneto
Serious diabetic ketoacidosis induced by insulin allergy and anti-insulin antibody in an individual with type 2 diabetes mellitus. Journal of diabetes investigation 13 (10) (2022)
Yasuharu Oe, Takatoshi Anno, Yukari Katsuhara, Ryo Sugahara, Miki Kobayashi, Mieko Yakusue, Masayo Tamura, Yukiko Kimura, Fumiko Kawasaki, Kohei Kaku, Hideaki Kaneto, Akira Kitanaka
A pitfall in hemoglobin A1c measurement with high performance liquid chromatography method in the diagnosis of onset of fulminant type 1 diabetes mellitus. Journal of diabetes investigation 13 (11) (2022)
Tomohiko Kimura, Kohei Kaku
Clinical relevance of dual agonist of glucagon and glucagon-like peptide-1 receptors to achieve functional restoration of first- and second-phase insulin secretion. Journal of diabetes investigation 13 (8) (2022)
Shuhei Nakanishi, Masashi Shimoda, Fuminori Tatsumi, Kenji Kohara, Atsushi Obata, Yukino Katakura, Junpei Sanada, Yoshiro Fushimi, Yuichiro Iwamoto, Mana Onishi, Hayato Isobe, Takashi Kusano, Kazunori Dan, Ryo Wamata, Hideyuki Iwamoto, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Effects of sedentary behavior and daily walking steps on body mass index and body composition: Prospective observational study using outpatient clinical data of Japanese patients with type 2 diabetes. Journal of diabetes investigation 12 (9) (2021)
Yasuhiro Matsubayashi, Alkihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku, Hirohito Sone
Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. Diabetes, obesity & metabolism 23 (7) (2021)
Shuhei Nakanishi, Masashi Shimoda, Fuminori Tatsumi, Kenji Kohara, Atsushi Obata, Junpei Sanada, Yoshiro Fushimi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Association between Grit Scales and adherence to regular hospital visits among Japanese patients with type 2 diabetes: Prospective observational study. Journal of diabetes investigation (2021)
Kohei Kaku, Takashi Kadowaki, Yutaka Seino, Taro Okamoto, Masayoshi Shirakawa, Asako Sato, Edward A O'Neill, Samuel S Engel, Keith D Kaufman
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. Diabetes, obesity & metabolism 23 (9) (2021)
Takahiro Abe, Yasuhiro Matsubayashi, Sayaka Muragishi, Akihiro Yoshida, Hideki Suganami, Kenichi Furusawa, Kazuya Fujihara, Shiro Tanaka, Kohei Kaku, Hirohito Sone
Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes. Journal of diabetes investigation 12 (10) (2021)
Julie Dubourg, Pascale Fouqueray, Damien Quinslot, Jean-Marie Grouin, Kohei Kaku
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week open-label, multicenter phase 3 trial. Diabetes, obesity & metabolism (2021)
Takashi Kadowaki, Fumiko Yamamoto, Yusuke Taneda, Yusuke Naito, Douglas Clark, Søren S Lund, Tomoo Okamura, Kohei Kaku
Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis. Expert opinion on drug safety 20 (6) (2021)
Takashi Kadowaki, Yutaka Seino, Kohei Kaku, Taro Okamoto, Miho Kameya, Asako Sato, Tomona Hirano, Nobuyuki Oshima, Ira Gantz, Edward A O'Neill, Samuel S Engel, null null
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. Diabetes, obesity & metabolism 23 (6) (2021)
Mitsuhisa Komatsu, Hirotaka Watada, Shizuka Kaneko, Bue F Ross Agner, Tomoyuki Nishida, Kohei Kaku
Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials. Journal of diabetes investigation 12 (9) (2021)
Yutaka Seino, Kohei Kaku, Takashi Kadowaki, Taro Okamoto, Asako Sato, Masayoshi Shirakawa, Edward A O'Neill, Samuel S Engel, Keith D Kaufman
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin. Diabetes, obesity & metabolism 23 (6) (2021)
Megumi Horiya, Takatoshi Anno, Mayuko Kawada, Haruki Yamada, Kaiou Takahashi, Haruka Takenouchi, Hideyuki Iwamoto, Fumiko Kawasaki, Katsumi Kurokawa, Hideaki Kaneto, Kohei Kaku, Koichi Tomoda
Pyogenic psoas abscess on the dorsal side, and bacterial meningitis and spinal epidural abscess on the ventral side, both of which were induced by spontaneous discitis in a patient with diabetes mellitus: A case report. Journal of diabetes investigation 12 (7) (2020)
Tomohiko Kimura, Kohei Kaku
New prospects for incretin-related drugs in the treatment of type 2 diabetes. Journal of diabetes investigation 12 (7) (2020)
Tomoe Kinoshita, Masashi Shimoda, Koji Nakashima, Yoshiro Fushimi, Yurie Hirata, Akihito Tanabe, Fuminori Tatsumi, Hidenori Hirukawa, Junpei Sanada, Kenji Kohara, Shintaro Irie, Tomohiko Kimura, Yoshiko Nakamura, Momoyo Nishioka, Atsushi Obata, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. Journal of diabetes investigation 11 (6) (2020)
Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Ryusuke Koshida, Hiroyuki Kameda, Masahiro Tamura, Kohei Kaku
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT). Journal of diabetes investigation 11 (4) (2020)
Yasuhiro Matsubayashi, Alkihiro Yoshida, Hideki Suganami, Taeko Osawa, Kazuo Furukawa, Hiroshi Suzuki, Mayuko Harada Yamada, Shiro Tanaka, Kohei Kaku, Yasuhiro Matsubayashi
Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin. Diabetes, obesity & metabolism 22 (6) (2020)
Kohei Kaku, Koichi Kisanuki, Mari Shibata, Takashi Oohira
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. Drug safety 42 (11) (2020)
Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani, Junko Toyoshima
Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study. Journal of diabetes investigation 11 (3) (2020)
Kazunori Utsunomiya, Ryusuke Koshida, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Kohei Kaku
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT). Journal of diabetes investigation 12 (2) (2020)
Yuichi Sato, Kiyohide Nunoi, Kohei Kaku, Alkihiro Yoshida, Hideki Suganami
Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss. Diabetes, obesity & metabolism 22 (2) (2019)
Kohei Kaku, Kazuyuki Ishida, Kohei Shimizu, Meguru Achira, Yuusuke Umeda
Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study. Journal of diabetes investigation 11 (2) (2019)
Kohei Kaku, Eiichi Araki, Yukio Tanizawa, Bue Ross Agner, Tomoyuki Nishida, Mattis Ranthe, Nobuya Inagaki
Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial. Diabetes, obesity & metabolism 21 (12) (2019)
Kohei Kaku, Yusuke Naito, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Seigo Kakiuchi, Kazunori Utsunomiya
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study). Journal of diabetes investigation 11 (2) (2019)
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. Journal of diabetes investigation 10 (6) (2019)
Kohei Kaku, Hiroyuki Isaka, Junko Toyoshima, Taishi Sakatani
Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial. Diabetes, obesity & metabolism 21 (6) (2019)
Shuhei Nakanishi, Hidenori Hirukawa, Masashi Shimoda, Fuminori Tatsumi, Kenji Kohara, Atsushi Obata, Seizo Okauchi, Yukino Katakura, Junpei Sanada, Yoshiro Fushimi, Momoyo Nishioka, Yuki Kan, Akiko Tomita-Mizoguchi, Hayato Isobe, Hideyuki Iwamoto, Kaio Takahashi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Impact of physical activity and sedentary time on glycated hemoglobin levels and body composition: Cross-sectional study using outpatient clinical data of Japanese patients with type 2 diabetes. Journal of diabetes investigation 11 (3) (2019)
Kohei Kaku
New concept of the glucagon-like peptide-1 signaling pathway on pancreatic insulin secretion. Journal of diabetes investigation 11 (2) (2019)
Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani, Junko Toyoshima
Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial. Diabetes, obesity & metabolism 21 (10) (2019)
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Kohei Kaku
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT). Journal of diabetes investigation 11 (1) (2019)
Kiyohide Nunoi, Yuichi Sato, Kohei Kaku, Akihiro Yoshida, Hideki Suganami
Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status. Diabetes, obesity & metabolism 21 (7) (2019)
Kohei Kaku, Masakazu Haneda, Yuko Tanaka, Ganghyuck Lee, Kosuke Shiki, Yuki Miyamoto, Fernando Solimando, Jisoo Lee, Christopher Lee, Jyothis George
Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. Diabetes, obesity & metabolism 21 (1) (2018)
Kohei Kaku, Yuichiro Yamada, Hirotaka Watada, Atsuko Abiko, Tomoyuki Nishida, Jeppe Zacho, Arihiro Kiyosue
Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Diabetes, obesity & metabolism 20 (5) (2018)
Motoshi Ouchi, Kenzo Oba, Hideki Suganami, Akihiro Yoshida, Tomoe Fujita, Tatsuya Suzuki, Masahiro Yasutake, Kohei Kaku
This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated". Diabetes, obesity & metabolism 20 (8) (2018)
Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku
Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). Diabetes, obesity & metabolism 20 (5) (2018)
Motoshi Ouchi, Kenzo Oba, Kohei Kaku, Hideki Suganami, Akihiro Yoshida, Yasunori Fukunaka, Promsuk Jutabha, Asuka Morita, Naoyuki Otani, Keitaro Hayashi, Tomoe Fujita, Tatsuya Suzuki, Masahiro Yasutake, Naohiko Anzai
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin. Diabetes, obesity & metabolism 20 (4) (2018)
Kiyohide Nunoi, Yuichi Sato, Kohei Kaku, Akihiro Yoshida, Hideki Suganami
Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes. Endocrinology, diabetes & metabolism 1 (2) (2018)
Kohei Kaku, Shingo Kuroda, Kazuyuki Ishida, Yuusuke Umeda
Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study. Diabetes, obesity & metabolism 20 (10) (2018)
Nobuya Inagaki, Shin-Ichi Harashima, Kohei Kaku, Kazuoki Kondo, Nobuko Maruyama, Makiko Otsuka, Yutaka Kawaguchi, Hiroaki Iijima
Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism 20 (4) (2017)